Hepatic complications

Late Effects of Childhood Cancer

Volumn , Issue , 2004, Pages 170-175

  Hudson, Melissa M ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84983588794     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (58)

1. Ingold JA, Reed GB, Kaplan HS, Bagshaw MA. Radiation hepatitis. Am J Roentgenol 1965; 93:200-208
2. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991; 21:109-122
3. Jirtle RL, Anscher MS, Alati T. Radiation sensitivity of the liver. Adv Radiat Biol 1990; 14:269-311
4. Tefft M. Radiation related toxicities in National Wilms’ Tumor Study Number 1. Int J Radiat Oncol Biol Phys 1977; 2:455-463
5. Tefft M, Mitus A, Das L, et al. Irradiation of the liver in children: review of the experience in the acute and chronic phases, and in the intact normal and partially resected. Am J Roentgenol Rad Ther Nucl Med 1970; 108:365-385
6. Tefft M, Mitus A, Jaffe. Irradiation of the liver in children: acute effects enhanced by concomitant chemotherapeutic administration. Am J Roentgenol Rad Ther Nucl Med 1971; 111:165-173
7. Kun LE, Camitta BM. Hepatopathy following irradiation and Adriamycin. Cancer 1978; 42:81-84
8. Bhanot P, Cushing B, Philippart A, et al. Hepatic irradiation and Adriamycin cardiotoxicity. J Pediatr 1979; 95:561-563
9. Johnson FL, Balis FM. Hepatopathy following irradiation and chemotherapy for Wilms’ tumor. Am J Pediatr Hematol Oncol 1982; 4:217-221
10. Flentje M, Weirich A, Potter R, Ludwig R. Hepatotoxicity in irradiated nephroblastoma patients during postoperative treatment according to SIOP9/GPOH. Radiother Oncol 1994; 31:222-228
11. Barnard JA, Marshall GS, Neblett WW, et al. Noncirrhotic portal fibrosis after Wilms’ tumor therapy. Gastroenterology 1986; 90:1054-1056
12. Lawrence TS, Robertson JM, Anscher MS, et al. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 1995; 31:1237-1248
13. Perry M. Chemotherapeutic agents and hepatotoxicity. Semin Oncol 1992; 19:551-565
14. Locasciulli A, Vergani GM, Uderzo C, et al. Chronic liver disease in children with leukemia in long-term remission. Cancer 1983; 52:1080-1087
15. Weber BL, Tanyer G, Poplack DG, et al. Transient acute hepatotoxicity of high-dose methotrexate therapy during childhood. Natl Cance Inst Monogr 1987:207-212
16. Bessho F, Kinumaki H, Yokota S, et al. Liver function studies in children with acute lymphocytic leukemia after cessation of therapy. Med Pediatr Oncol 1994; 23:111-115.
17. Ballauff A, Krahe J, Jansen B, et al. [Chronic liver disease after treatment of malignancies in children]. Klin Padiatr 1999; 211:49-52
18. Lascari AD, Givler RL, Soper RT, Hill LF. Portal hypertension in a case of acute leukemia treated with antimetabolites for ten years. N Engl J Med 1968; 279:303-306
19. Ruymann FB, Mosijczuk AD, Sayers RJ. Hepatoma in a child with methotrexate-induced hepatic fibrosis. JAMA 1977; 238: 2631-2633
20. Nesbit M, Krivit W, Heyn R, Sharp H. Acute and chronic effects of methotrexate on hepatic, pulmonary, and skeletal systems. Cancer 1976; 37:1048-1057
21. Einhorn M, Davidsohn I. Hepatotoxicity of mercaptopurine. JAMA 1964; 188:802-806
22. Green DM, Norkool P, Breslow NE, et al. Severe hepatic toxicity after treatment with vincristine and dactinomycin using singledose or divided-dose schedules: a report from the National Wilms’ Tumor Study. J Clin Oncol 1990; 8:1525-1530
23. Raine J, Bowman A, Wallendszus K, Pritchard J. Hepatopathy-thrombocytopenia syndrome a complication of dactinomycin therapy for Wilms’ tumor: a report from the United Kingdom Childrens Cancer Study Group. J Clin Oncol 1991; 9:268-273
24. Dahl MG, Gregory MM, Scheuer PJ. Methotrexate hepatotoxicity in psoriasis comparison of different dose regimens. Br Med J 1972; 1:654-656
25. Parker D, Bate CM, Craft AW, et al. Liver damage in children with acute leukaemia and non-Hodgkin’s lymphoma on oral maintenance chemotherapy. Cancer Chemother Pharmacol 1980; 4:121-127
26. McIntosh S, Davidson DL, O’Brien RT, Pearson HA. Methotrexate hepatotoxicity in children with leukemia. J Pediatr 1977; 90:1019-1021
27. Topley JM, Benson J, Squier MV, Chessells JM. Hepatotoxicity in the treatment of acute lymphoblastic leukemia. Med Pediatr Oncol 1979; 7:393-399
28. Colsky J, Greenspan EM, Warren TN. Hepatic fibrosis in children with acute leukemia after therapy with folic acid antagonists. Arch Pathol Lab Med 1955; 59:198-206
29. Hutter RVP, Shipkey FH, Tan CTC, et al. Hepatic fibrosis in children with acute leukemia: a complication of therapy. Cancer 1960; 13:288-307
30. Hersh EM, Wong VG, Henderson ES, Freireich E. Hepatotoxic effects of methotrexate. Cancer 1966; 19:600-606
31. Sullivan KM, Agura E, Anasetti C, et al. Chronic graftversus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250-259
32. Fisher VL. Long-term follow-up in hematopoietic stem-cell transplant patients. Pediatr Transplant 1999; 3(Suppl. 1): 122-129
33. Knapp AB, Crawford JM, Rappeport JM, Gollan JL. Cirrhosis as a consequence of graft versus host disease. Gastroenterology 1987; 92:513-519
34. Socie G, Stone JV, Wingard JR, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 1999; 341: 14-21
35. Yau JC, Zander AR, Srigley JR, et al. Chronic graft-versus-host disease complicated by micronodular cirrhosis and esophageal varices. Transplantation 1986; 41:129-130
36. http://www.fda.gov/cber/products/testkitshtm. 04/29/02
37. Seeff LB, Koff RS. Evolving concepts of the clinical and serologic consequences of hepatitis B virus infection. Semin Liver Dis 1986; 6:11-22.
38. Villano SA, Vlahov D, Nelson KE, et al. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999; 29:908-914
39. Paul IM, Sanders J, Ruggiero F, et al. Chronic hepatitis C virus infections in leukemia survivors: prevalence, viral load, and severity of liver disease. Blood 1999; 93:3672-3677
40. Locasciulli A, Testa M, Valsecchi MG, et al. Morbidity and mortality due to liver disease in children undergoing allogeneic bone marrow transplantation: a 10-year prospective study. Blood 1997; 90:3799-3805
41. Shakil AO, Conry-Cantilena C, Alter HJ, et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med 1995; 123:330-337
42. Yano M, Yatsuhashi H, Inoue O, et al. Epidemiology and long term prognosis of hepatitis C virus infection in Japan. Gut 1993; 34:S13-16
43. Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19:1513-1520
44. Haydon GH, Flegg PJ, Blair CS, et al. The impact of chronic hepatitis C virus infection on HIV disease and progression in intravenous drug users. Eur J Gastroenterol Hepatol 1998; 10:485-489
45. Lucidarme D, Dumas F, Arpurt J, et al. and a French Collaborative Study Group. Natural history of hepatitis C: age at the time of transfusion might be an important predictive factor of progression to cirrhosis. Gastroenterology 1997; 112:A516
46. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349:825-832
47. Vogt M, Lang T, Frosner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999; 341:866-870.
48. Fink FM, Hocker-Schulz S, Mor W, et al. Association of hepatitis C virus infection with chronic liver disease in paediatric cancer patients. Eur J Pediatr 1993; 152:490-492
49. Arico M, Maggiore G, Silini E, et al. Hepatitis C virus infection in children treated for acute lymphoblastic leukemia. Blood 1994; 84:2919-2922
50. Locasciulli A, Testa M, Pontisso P, et al. Prevalence and natural history of hepatitis C infection in patients cured of childhood leukemia. Blood 1997; 90:4628-4633
51. Locasciulli A, Cavalletto D, Pontisso P, et al. Hepatitis C virus serum markers and liver disease in children with leukemia during and after chemotherapy. Blood 1993; 82:2564-2567
52. Neilson JR, Harrison P, Skidmore SJ, et al. Chronic hepatitis C in long term survivors of haematological malignancy treated in a single centre. J Clin Pathol 1996; 49:230-232
53. Cesaro S, Petris MG, Rossetti F, et al. Chronic hepatitis C virus infection after treatment for pediatric malignancy. Blood 1997; 90:1315-1320
54. Strickland DK, Riely CA, Patrick CC, et al. Hepatitis C infection among survivors of childhood cancer. Blood 2000; 95:3065-3070
55. Cesaro S, Rossetti F, De Moliner L, et al. Interferon for chronic hepatitis C in patients cured of malignancy. Eur J Pediatr 1994; 153:659-662
56. Strickland DK, Jenkins JJ, Hudson MM. Hepatitis C infection and hepatocellular carcinoma after treatment of childhood cancer. J Pediatr Hematol Oncol 2001; 23:527-529
57. Locasciulli A, Testa M, Pontisso P, et al. Hepatitis C virus genotypes and liver disease in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 19:237-240
58. Bernard B, Lebrec D, Mathurin P, et al. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Hepatology 1997; 25:63-70.